BACKGROUND: After endoscopic radiofrequency ablation (RFA) of dysplastic Barrett's esophagus (BE), endoscopic biopsy samples are obtained to assess response to therapy. Whether these biopsies are of adequate depth to assess efficacy is unknown. OBJECTIVE: To compare the depth of endoscopic biopsy samples after RFA with those of untreated controls and to determine the prevalence of subepithelial structures in endoscopic biopsy fragments. DESIGN: Secondary analysis of the AIM Dysplasia Trial, a multicenter, randomized, sham-controlled study. SETTING: Nineteen treatment centers. PATIENTS: Subjects with dysplastic BE, either status post RFA or ablation naïve (sham). MAIN OUTCOME MEASUREMENTS: The proportion of biopsy samples demonstrating subepithelial structures, stratified by tissue type (columnar vs squamous) in sham- and RFA-treated subjects. RESULTS:A total of 5648 biopsy fragments were analyzed from 113 subjects (78 RFA, 35 sham; mean 50.0 fragments per subject). Most fragments (4653, 82.4%) contained subepithelium. Squamous biopsy samples from RFA and sham subjects demonstrated subepithelium at similar rates (78.4% vs 79.1%, respectively, P = not significant [NS]). Columnar biopsy samples from RFA and sham subjects also included subepithelium at similar rates (99.0% vs 98.8%, respectively, P = NS). Regardless of treatment assignment, more columnar than squamous biopsy samples demonstrated subepithelium (98.8% vs 78.5%, P < .001). LIMITATIONS: Biopsy samples were not individually mounted. CONCLUSIONS: In both squamous and columnar tissue, endoscopic biopsy samples after RFA were as likely to demonstrate subepithelium as untreated controls. Almost 80% of all biopsy samples were adequate to evaluate for subsquamous intestinal metaplasia. The primary determinant of biopsy depth is the type of epithelium that underwent biopsy, with squamous less likely to yield subepithelium than columnar. Biopsy samples after RFA appear to be of adequate depth to assess response to therapy. (Clinical trial registration number NCT00282672.). Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: After endoscopic radiofrequency ablation (RFA) of dysplastic Barrett's esophagus (BE), endoscopic biopsy samples are obtained to assess response to therapy. Whether these biopsies are of adequate depth to assess efficacy is unknown. OBJECTIVE: To compare the depth of endoscopic biopsy samples after RFA with those of untreated controls and to determine the prevalence of subepithelial structures in endoscopic biopsy fragments. DESIGN: Secondary analysis of the AIM Dysplasia Trial, a multicenter, randomized, sham-controlled study. SETTING: Nineteen treatment centers. PATIENTS: Subjects with dysplastic BE, either status post RFA or ablation naïve (sham). MAIN OUTCOME MEASUREMENTS: The proportion of biopsy samples demonstrating subepithelial structures, stratified by tissue type (columnar vs squamous) in sham- and RFA-treated subjects. RESULTS: A total of 5648 biopsy fragments were analyzed from 113 subjects (78 RFA, 35 sham; mean 50.0 fragments per subject). Most fragments (4653, 82.4%) contained subepithelium. Squamous biopsy samples from RFA and sham subjects demonstrated subepithelium at similar rates (78.4% vs 79.1%, respectively, P = not significant [NS]). Columnar biopsy samples from RFA and sham subjects also included subepithelium at similar rates (99.0% vs 98.8%, respectively, P = NS). Regardless of treatment assignment, more columnar than squamous biopsy samples demonstrated subepithelium (98.8% vs 78.5%, P < .001). LIMITATIONS: Biopsy samples were not individually mounted. CONCLUSIONS: In both squamous and columnar tissue, endoscopic biopsy samples after RFA were as likely to demonstrate subepithelium as untreated controls. Almost 80% of all biopsy samples were adequate to evaluate for subsquamous intestinal metaplasia. The primary determinant of biopsy depth is the type of epithelium that underwent biopsy, with squamous less likely to yield subepithelium than columnar. Biopsy samples after RFA appear to be of adequate depth to assess response to therapy. (Clinical trial registration number NCT00282672.). Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
Authors: Virender K Sharma; Kenneth K Wang; Bergein F Overholt; Charles J Lightdale; M Brian Fennerty; Patrick J Dean; Douglas K Pleskow; Ram Chuttani; Alvaro Reymunde; Nilda Santiago; Kenneth J Chang; Michael B Kimmey; David E Fleischer Journal: Gastrointest Endosc Date: 2007-02 Impact factor: 9.427
Authors: Roos E Pouw; Joep J Gondrie; Agnieszka M Rygiel; Carine M Sondermeijer; Fiebo J ten Kate; Robert D Odze; Michael Vieth; Kausilia K Krishnadath; Jacques J Bergman Journal: Am J Gastroenterol Date: 2009-04-21 Impact factor: 10.864
Authors: Bergein F Overholt; Charles J Lightdale; Kenneth K Wang; Marcia I Canto; Steven Burdick; Roger C Haggitt; Mary P Bronner; Shari L Taylor; Michael G A Grace; Michelle Depot Journal: Gastrointest Endosc Date: 2005-10 Impact factor: 9.427
Authors: David E Fleischer; Bergein F Overholt; Virender K Sharma; Alvaro Reymunde; Michael B Kimmey; Ram Chuttani; Kenneth J Chang; Charles J Lightdale; Nilda Santiago; Douglas K Pleskow; Patrick J Dean; Kenneth K Wang Journal: Gastrointest Endosc Date: 2008-06-17 Impact factor: 9.427
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag Journal: Ann N Y Acad Sci Date: 2011-09 Impact factor: 5.691
Authors: Angelique Levert-Mignon; Michael J Bourke; Sarah J Lord; Andrew C Taylor; Antony R Wettstein; Melanie Edwards; Natalia K Botelho; Rebecca Sonson; Chatura Jayasekera; Oliver M Fisher; Melissa L Thomas; Finlay Macrae; Damian J Hussey; David I Watson; Reginald V Lord Journal: United European Gastroenterol J Date: 2016-07-07 Impact factor: 4.623
Authors: Cary C Cotton; W Asher Wolf; Sarina Pasricha; Nan Li; Ryan D Madanick; Melissa B Spacek; Kathleen Ferrell; Evan S Dellon; Nicholas J Shaheen Journal: Gastrointest Endosc Date: 2015-03-24 Impact factor: 9.427
Authors: Christina L Greene; Stephanie G Worrell; Stephen E Attwood; Parakrama Chandrasoma; Kenneth Chang; Tom R DeMeester; Reginald V Lord; Elizabeth Montgomery; Oliver Pech; John Vallone; Michael Vieth; Kenneth K Wang; Steven R DeMeester Journal: J Gastrointest Surg Date: 2015-12-21 Impact factor: 3.452